NeoGenomics, Inc. (NASDAQ: NEO) reported preliminary revenue for the fourth quarter of 2025 at $190 million, up 11% year‑over‑year from $172 million in Q4 2024. The figure also exceeds the consensus estimate of $188.07 million by $1.93 million, a 1.0% beat that reflects strong demand in the company’s core clinical testing segment, particularly next‑generation sequencing (NGS) and liquid biopsy services.
Full‑year 2025 revenue is projected at $727 million, a 10% increase from $661 million in 2024 and a $1.95 million (0.27%) beat over the consensus estimate of $725.05 million. The preliminary figure sits comfortably within the revised guidance range of $720 million to $726 million that NeoGenomics issued in July 2025, indicating that the company is on track to meet its updated expectations despite earlier headwinds such as pharma revenue softness and non‑clinical challenges.
The company’s clinical testing revenue grew driven by the continued uptake of its NGS platform, which saw a 24% rise in Q3 2025 and accounts for roughly one‑third of total clinical revenue. Liquid biopsy revenue also expanded following the July 2025 launch of the NEO PanTracer™ LBx test, positioning NeoGenomics to capture a share of the $3 billion–$5 billion liquid biopsy market. These gains offset modest pressure in legacy product lines, allowing the company to maintain a healthy revenue trajectory.
Management highlighted the CFO transition as a strategic move to support scaling operations. Chief Financial Officer Jeff Sherman will retire and become Executive Vice President on March 2, 2026, while Life‑sciences veteran Abhishek Jain will assume the CFO role on the same date. Sherman’s retirement will be effective April 14, 2026. CEO Tony Zook praised the transition, noting that “Abhishek brings a proven track record of guiding life‑sciences companies through rapid growth and transformation, and I look forward to his financial leadership as we continue to scale our organization and pursue multi‑billion‑dollar addressable markets in advanced cancer testing.”
Analysts noted the revenue beat and the company’s continued focus on high‑growth segments. The market reaction was positive, with analysts acknowledging NeoGenomics’ ability to sustain double‑digit revenue growth while navigating headwinds in non‑clinical and pharma segments. The CFO transition is viewed as a confidence signal that the company is positioning itself for continued expansion in precision oncology diagnostics.
The preliminary results underscore NeoGenomics’ resilience and its strategic emphasis on NGS and liquid biopsy, both of which are expected to drive future growth. The company’s ability to meet or exceed revised guidance while managing a leadership transition suggests strong operational execution and a clear path forward for investors.
The announcement also signals that NeoGenomics is maintaining its focus on scaling operations and pursuing new growth opportunities in precision oncology diagnostics, reinforcing its competitive position in the community oncology market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.